ARTICLE | Deals
Quick exit for Medicxi as Incyte buys vitiligo company Villaris
Incyte pays $70M up front to add UMass spinout’s vitiligo candidate, complementing topical ruxolitinib
October 3, 2022 9:09 PM UTC
Medicxi’s 2019 seed investment in UMass spinout Villaris has resulted in a quick exit for the firm via Incyte’s acquisition of the company and its sole asset, a mAb to treat vitiligo.
Incyte Corp. (NASDAQ:INCY) will pay $70 million up front to acquire Villaris Therapeutics Inc. in a heavily back-loaded deal that includes $310 million in developmental and regulatory milestones, plus nearly $1.1 billion in commercial milestones...
BCIQ Target Profiles